BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11704798)

  • 1. Autologous reconstitution combined with durable leukemic remission after allogeneic BMT for CML: absence of persistence of a donor-derived T cell effector population.
    Maury S; Belhadj K; Chami I; Kuentz M; Cordonnier C; Bories D
    Bone Marrow Transplant; 2001 Oct; 28(7):717-20. PubMed ID: 11704798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S; Barnett L; Heller G
    Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L; Eder M; Dammann E; Battmer K; Stucki A; Heil G; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
    Wassmann B; Klein SA; Scheuring U; Pfeifer H; Martin H; Gschaidmeier H; Hoelzer D; Ottmann OG
    Bone Marrow Transplant; 2001 Oct; 28(7):721-4. PubMed ID: 11704799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease in chronic myeloid leukaemia.
    Cross NC
    Hematol Cell Ther; 1998 Oct; 40(5):224-8. PubMed ID: 9844816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous reconstitution with BCR-ABL-negative haematopoiesis after T cell-depleted allogeneic BMT for CML.
    Serrano J; Román J; Castillejo JA; Sánchez J; Navarro JA; Martín C; Herrera C; Torres A
    Bone Marrow Transplant; 1998 Sep; 22(6):599-601. PubMed ID: 9758352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Durable molecular remission in a patient with chronic myelogenous leukemia and host-derived hematopoiesis after allogeneic bone marrow transplantation.
    Wakui M; Okamoto S; Ishida A; Tanosaki R; Mori T; Kawai Y; Ohshima S; Ikeda Y
    Bone Marrow Transplant; 1996 Oct; 18(4):801-4. PubMed ID: 8899199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse.
    Hughes TP; O'Shea P; Morgan G; Martiat P; Goldman JM
    Bone Marrow Transplant; 1991; 7 Suppl 2():23. PubMed ID: 1878700
    [No Abstract]   [Full Text] [Related]  

  • 11. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia.
    Jiang YZ; Cullis JO; Kanfer EJ; Goldman JM; Barrett AJ
    Bone Marrow Transplant; 1993 Feb; 11(2):133-8. PubMed ID: 8435662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL transcripts detected by polymerase chain reaction (PCR) after allogenic BMT for CML: analysis of 32 longterm disease free patients.
    Guerrasio A; Zaccaria A; Rosso C; Scaravaglio P; Rege Cambrin G; Bertolli VG; Saglio G; Tassinari A; Testoni N; Rosti G
    Bone Marrow Transplant; 1991; 7 Suppl 2():22. PubMed ID: 1878699
    [No Abstract]   [Full Text] [Related]  

  • 15. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autologous hematopoietic stem cell transplantation in chronic myeloid leukemia].
    Boqué C; Grañena A
    Sangre (Barc); 1998 Apr; 43(2):155-63. PubMed ID: 9656777
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolonged remission of accelerated phase Philadelphia chromosome negative chronic myeloid leukemia following autologous recovery of normal hematopoietic elements after busulfan/cyclophosphamide and allogeneic marrow transplantation.
    Kapoor N; Keever CA; Hsu SH; Copelan EA; Tutschka PJ
    Bone Marrow Transplant; 1992 Feb; 9(2):143-5. PubMed ID: 1349249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The detection and significance of minimal residual disease in chronic myeloid leukemia.
    Radich JP
    Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.